Profilo
Romuald Corbau worked as Chief Scientific Officer at Freeline Therapeutics Holdings Ltd. from 2020 to 2021.
Dr. Corbau worked as Chief Scientific Officer at GenEdit, Inc. Dr. Corbau worked as Chief Scientific Officer at Adverum Biotechnologies, Inc. from 2024 to 2025.
Dr. Corbau graduated from Université des Sciences et Technologies de Lille.
Precedenti posizioni note di Romuald Corbau
| Società | Posizione | Fine |
|---|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Direttore Tecnico/Scientifico/R&S | 09/12/2025 |
| FREELINE THERAPEUTICS HOLDINGS PLC | Direttore Tecnico/Scientifico/R&S | 20/08/2021 |
GenEdit, Inc.
GenEdit, Inc. BiotechnologyHealth Technology Develops next generation therapeutics for genetic diseases | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Romuald Corbau
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Società collegate
| Aziende private | 4 |
|---|---|
Université des Sciences et Technologies de Lille
Université des Sciences et Technologies de Lille Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and sells novel gene therapies | Health Technology |
GenEdit, Inc.
GenEdit, Inc. BiotechnologyHealth Technology Develops next generation therapeutics for genetic diseases | Health Technology |
Freeline Therapeutics Holdings Plc
Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Develops and manufactures next-generation gene therapies | Health Technology |
















